Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy are holding back sales at the pharma ...
Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...
The boss of the Wegovy firm linked its reduced guidance to the market for weight-loss treatments being ‘more competitive than ...
The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.
Novo Nordisk stock was rising after it posted quarterly earnings. The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.
Novo Nordisk today presented new data from the OASIS 4 phase 3 trial that explored a variety of patients and hypotheses, ...
52mon MSN
Novo Nordisk's obesity pill shows cardiovascular benefits, comparable efficacy to injection
Pedersen COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk presented new data on Wednesday showing its experimental weight-loss ...
Company cuts 9,000 jobs and lowers profit forecast as Wegovy sales slow. Q3 operating profit down 30% on competition ...
Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback